NCT04416126View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Ornithine Transcarbamylase Deficiency
Interventions
BIOLOGICAL

ARCT-810

ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.

OTHER

Placebo

The placebo for this study is 0.9% sterile saline.

Trial Locations (1)

Unknown

Auckland Clinical Studies (ACS) Ltd., Auckland

Sponsors
All Listed Sponsors
lead

Arcturus Therapeutics, Inc.

INDUSTRY

NCT04416126 - Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter